OH
TPST icon

Orbis Holdings’s Tempest Therapeutics TPST Stock Holding History

Orbis Holdings’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$20.4M Hold
715
– – 0.16% 53
2015
Q3 		$17.7M Buy
715
+249
+53% +$16.8M 0.15% 54
2015
Q2 		$39.5M Buy
466
+124
+36% +$11.4M 0.3% 47
2015
Q1 		$34.7M Buy
+342
New +$45.5M 0.28% 49

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Orbis Holdings's TPST Position: Q4 2015 in Review

Orbis Holdings held its Tempest Therapeutics (TPST) position steady in Q4 2015 at 715 shares worth $20.4M. The position accounts for 0.16% of the portfolio, ranked #53.

Orbis Holdings first reported a position in TPST in Q1 2015 and has held it in 4 quarters since. The position peaked at $39.5M in Q2 2015. 78 funds tracked by Wall St. Rank hold TPST as of Q4 2015.

  • Orbis Holdings held 715 shares of Tempest Therapeutics worth $20.4M as of Q4 2015.
  • Orbis Holdings left its Tempest Therapeutics share count unchanged in Q4 2015.
  • Tempest Therapeutics made up 0.16% of Orbis Holdings's portfolio in Q4 2015, its #53 holding.
  • Orbis Holdings first reported a position in Tempest Therapeutics in Q1 2015 and has held it in 4 quarters since.
  • Orbis Holdings's Tempest Therapeutics position peaked at $39.5M in Q2 2015.
  • 78 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2015.

Based on Orbis Holdings's 13F filing for Q4 2015, filed 16 Feb 2016.